Vabomere

DRUG2 trials

Sponsors

Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.), Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)

Conditions

Abdominal InfectionAcute PyelonephritisBacteremiaBacterial InfectionsHospital Acquired Bacterial PneumoniaUrinary Tract Infection ComplicatedVentilator-associated Bacterial Pneumonia

Phase 1

Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections

Active, not recruitingNCT02687906

Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)Bacterial Infections

Start: 2016-07-31End: 2025-12-31Updated: 2025-07-25

Phase 3

Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults

CompletedNCT02168946

Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)Abdominal Infection, Acute Pyelonephritis, Bacteremia +3

Start: 2014-07-31End: 2017-07-21Updated: 2019-03-04

Related Papers

Clinical Outcomes of Patient Subgroups in the TANGO II Study.

2021-02-094 citations

Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.

2018-10-01317 citations